Andre Uddin of Research Capital Corp thinks investors will want to own a piece of Theratechnologies going forward, since its pipeline of drug prospects is worth it. Uddin delivered a report on THTX to clients on Wednesday where he reiterated a Buy rating while lowering his target price to $3.50.
Douglas W. Loe, analyst for Leede Jones Gable, reviewed the latest news from Theratechnologies in an update to clients on Monday and reiterated a “Speculative Buy” rating on the stock.